Article
ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia.
Journal of translational medicine - 22 May 2019
Swindell William R, Kruse Colin P S, List Edward O, Berryman Darlene E, Kopchick John J
Abstract excerpt
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a debilitating disease with few treatment options. Progress towards new therapies requires validated disease biomarkers, but there is no consensus on which fluid-based measures are most informative. METHODS: This study analyzed microarray data derived from blood samples of patients with ALS (n = 396), ALS mimic diseases (n = 75), and healthy controls (n = 645)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.